“Four-Weekly Dosing Intervals With Subcutaneous Spesolimab Appear to Be Required for Optimal Prevention of Generalized Pustular Psoriasis Flares: Data from the EFFISAYIL® 2 and EFFISAYIL® ON Trials”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 6, Nov. 2024, p. s492, https://doi.org/10.25251/skin.8.supp.492.